Abstract | AIMS: METHODS AND RESULTS:
C-reactive protein, interleukin-6 (IL-6), and tumour necrosis factor-alpha ( TNF-alpha) serum levels were assessed in 337 patients enrolled in either the placebo or the pexelizumab 24 h infusion group. Higher C-reactive protein and IL-6 levels at baseline, 24 h, and 72 h were strongly associated with increased subsequent death (P<0.002 at baseline and 24 h, P<0.02 at 72 h); and all baseline marker levels with death or cardiogenic shock (P<0.03) within 90 days. C-reactive protein and IL-6 levels were similar at baseline, but significantly lower 24 h later with pexelizumab, when compared with placebo (17.1 vs. 25.5 mg/L, P=0.03 and 51.0 vs. 63.8 pg/mL, P=0.04, respectively). At 72 h, corresponding levels were similar, whereas TNF-alpha was slightly higher (P=0.04) in the treated group. CONCLUSION:
|
Authors | Pierre Théroux, Paul W Armstrong, Kenneth W Mahaffey, Judith S Hochman, Kevin J Malloy, Scott Rollins, Jose C Nicolau, Joel Lavoie, The Minh Luong, Jeb Burchenal, Christopher B Granger |
Journal | European heart journal
(Eur Heart J)
Vol. 26
Issue 19
Pg. 1964-70
(Oct 2005)
ISSN: 0195-668X [Print] England |
PMID | 15872036
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Biomarkers
- Complement C5
- Interleukin-6
- Single-Chain Antibodies
- Tumor Necrosis Factor-alpha
- C-Reactive Protein
- pexelizumab
|
Topics |
- Aged
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Biomarkers
(blood)
- C-Reactive Protein
(metabolism)
- Complement C5
(antagonists & inhibitors)
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Interleukin-6
(blood)
- Male
- Middle Aged
- Myocardial Infarction
(blood, drug therapy, mortality)
- Single-Chain Antibodies
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(analysis)
|